Blood Pressure Clinical Trial
Official title:
Mechanisms of Blood Pressure Dysfunction in Transmen Receiving Testosterone
Verified date | October 2022 |
Source | Yale University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this research is to explore the effects of chronic androgen exposure on sympathetic nervous system activity (SNSA) and baroreflex control of blood pressure responses in transgender men (trans men) taking gender affirming hormone therapy (HT). Blood pressure, baroreflex gain, and frequency of sympathetic responses to changes in blood pressure will be assessed in trans men and a control group of cisgender women. To fully understand HT effects on blood pressure regulation in trans men, it is crucial to understand how both SNSA, and the pattern of SNSA, can be influenced by high levels of androgen exposure in the female cardiovascular system, as well as how the two regulatory components may interact.
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | June 30, 2024 |
Est. primary completion date | July 1, 2023 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Female |
Age group | 18 Years to 45 Years |
Eligibility | Inclusion Criteria: - Both groups (trans men and cisgender women) must be healthy and non-smoking. Control participants must be cisgender women with regular menses every 26-34 days. Trans men participants must be currently receiving testosterone for gender affirming hormone therapy where physiologic doses of exogenous Dihydrotestosterone have been administered (via injection or transdermal application) for at least 3 months as prescribed by their local endocrine provider as part of their clinically indicated hormone therapy. Doses can vary depending on the size and goals of each patient, but blood testosterone will be between 400-1000 ng/dl. Exclusion Criteria: - Subjects who smoke, have diabetes, or BP>140/90 will be excluded. - Subjects will not be taking medications during the study, including any insulin-sensitizing or cardiovascular medications. - Subjects are excluded if they have lost > 5 kg of weight within the past 6 months or perform high-intensity exercise > 3 times/week. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Yale University | The John B. Pierce Laboratory |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Muscle Sympathetic Nerve Activity (MSNA) | MSNA is recorded continuously at rest and during O/LBNP protocols with a tungsten microelectrode (0.2 diameters insulated shaft tapered to an uninsulated tip of ~1-5 µm) inserted percutaneously into the median nerve. Multiunit, postganglionic MSNA is distinguished from other sources of nerve activity by the presence of spontaneous pulse synchronous bursts, increased activity when the subject holds their breath or clenches their first (stretches forearm muscles around median nerve), or if activity does not change when the skin is stimulated by light brushing or stroking (indicates lack of skin nerve activity). Bursts of MSNA at rest and during LBNP are quantified as total activity (AU/min), burst frequency (bursts/min) and burst incidence (bursts/100 heartbeats). The MSNA burst incidence is expressed in bursts/100 heartbeats to normalize for differences in heart rate among subjects. | 3 hours | |
Primary | Systolic Blood Pressure (SBP) | SBP is measured continuously with a Finometer beat-to-beat blood pressure measurement system at rest and during O/LBNP protocols. Units are mm Hg. | 3 hours | |
Primary | Diastolic Blood Pressure (DBP) | DBP is measured continuously with a Finometer beat-to-beat blood pressure measurement system at rest and during O/LBNP protocols. Units are mm Hg. | 3 hours | |
Primary | Mean Arterial Pressure (MAP) | MAP at rest and during O/LBNP protocols is calculated as 1/3(SBP-DBP)+DBP using the beat-to-beat SBP and DBP measurements taken with the Finometer system. Units are mm Hg. | 3 hours | |
Primary | Sympathetic Baroreflex (BR) Gain | Sympathetic BR gain is used as an index of sympathetic (neural) control of blood pressure, where gain is determined by the slope of the linear relationship between MSNA (burst/100 heartbeats) and DBP (mm Hg) at rest and during LBNP. The relationship produces a negative slope in that for a given subject, when DBP falls below the normal level sustained at rest, sympathetic activity increases to restore DBP back to that normal level. Thus, more MSNA bursts are observed at lower levels of DBP and vice versa. A steeper (more negative) slope suggests greater sensitivity of the baroreceptors to changes in blood pressure, and thereby more effective sympathetic control of blood pressure. A flatter slope suggests impaired BR sensitivity and blood pressure dysfunction, which is expected for the trans men group compared to cisgender women controls. | 3 hours | |
Primary | Frequency in the Neural Cardiovascular Control | The frequency of SBP, DBP and heart rate during OLBNP is analyzed in Matlab in a linear time-invariant system (LTI) framework. Heart rate and BP measures taken during OLBNP are low-pass filtered (0.05 Hz estimated example) and corrected for end-effects using a Hamming window. The derived impulse responses (IRs) are 1/3rd octave smoothed before calculating the frequency power spectra (0.001-0.05 Hz estimated example). The power of DBP and SBP at the OLBNP frequency are anticipated to be independently inversely related to the efficiency of BP control. Further, the difference in heart rate and SBP, and in heart rate and DBP, power at those frequencies reflects the degree of autonomic function, analogous to baroreflex gain. | 0.5 hours | |
Primary | Electrocardiogram (ECG) | A 3-lead ECG is continuously recorded at rest and during the O/LBNP protocols. The R-wave of the QRS complex of the ECG recording will be used for measures of pulse interval by determining the amount of time in seconds between the R-waves of 2 consecutive QRS complexes. | 3 hours | |
Secondary | Brachial Artery Mean Blood Flow Velocity | Mean blood flow velocity in the brachial artery will be examined at rest and during LBNP using Doppler ultrasound velocimetry. Blood flow velocity spectra and arterial diameter are measured simultaneously with a Doppler probe and SonoScape S2 ultrasound system. The brachial artery is imaged with a 6.0-MHz linear array probe positioned at a 45° angle over the skin at the distal one-third of the upper arm. Brachial blood flow is expected to decrease as the level of LBNP increases and induces a greater orthostatic challenge. For example, blood flow would be highest at the -10LBNP stage and continually decrease during the following stages of -20, -30 and finally -40LBNP, where blood flow would be the lowest. | 3 hours | |
Secondary | Cardiovagal Baroreflex (BR) Gain | Cardiovagal BR gain is determined by the slope of the linear relationship between R-R Interval (seconds) and SBP (mm Hg) at rest and during LBNP. R-R Intervals are obtained from the ECG recording and SBP is obtained from the beat-to-beat measures taken by the Finometer. | 3 hours |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03255187 -
Effect of Dietary Supplemental Fish Oil in Alleviating Health Hazards Associated With Air Pollution
|
N/A | |
Completed |
NCT05997303 -
Continuous Norepinephrine Administration and Blood Pressure Stability During Anesthetic Induction
|
N/A | |
Recruiting |
NCT04575194 -
Study of the Cardiometabolic Effects of Obesity Pharmacotherapy
|
Phase 4 | |
Completed |
NCT03918486 -
Caretaker vs. Routine Blood Pressure Sphygmomanometer
|
||
Completed |
NCT03410342 -
The Effects of Types of Fruits and Vegetables on Vascular Function
|
N/A | |
Active, not recruiting |
NCT05062161 -
Sleep Duration and Blood Pressure During Sleep
|
N/A | |
Not yet recruiting |
NCT04087070 -
Blood Pressure Estimation Using Noninvasive Biosignals During Pediatric Anesthesia
|
||
Completed |
NCT03294928 -
Arterial Waveform Analysis Applying Different Positive End-Expiratory Pressure (PEEP) Levels in Healthy Volunteers
|
N/A | |
Completed |
NCT03859934 -
Metabolic Effects of Melatonin Treatment
|
Phase 1 | |
Completed |
NCT03997461 -
Comparison of Arterial Tonometry Sensor With Standard Oscillometric Blood Pressure Monitoring Device
|
N/A | |
Completed |
NCT03290716 -
Diet, ExerCIse and carDiovascular hEalth (DECIDE) - Salt Reduction Strategies for the Elderly in Nursing Homes in China
|
N/A | |
Recruiting |
NCT05196048 -
Blood Pressure Sensor of Watch-type Device With ECG Technology
|
||
Recruiting |
NCT06460233 -
Blood Pressure Changes After Bariatric Surgery
|
||
Terminated |
NCT03325933 -
Resistance Training and Cardiometabolic Health
|
N/A | |
Not yet recruiting |
NCT06405880 -
Pharmacist Case Finding and Intervention for Vascular Prevention Trial
|
N/A | |
Completed |
NCT02924454 -
Effects of Lipid Emulsion on the Pharmacokinetic and Pharmacodynamic Properties of Metoprolol.
|
Phase 4 | |
Completed |
NCT02451059 -
Reducing Socioeconomic Disparities in Health at Pediatric Visits
|
N/A | |
Active, not recruiting |
NCT02670967 -
Effects of Soluble Fiber on Blood Pressure: A Meta-analysis of Randomly-controlled Trials
|
N/A | |
Completed |
NCT02271633 -
Nitrate Supplementation; Source
|
Phase 4 | |
Completed |
NCT02239744 -
Intervention Study on the Health Impact of Air Filters in Chinese Adults
|
N/A |